Format
Sort by
Items per page

Send to

Choose Destination

Best matches for Rüttinger D[au]:

Colony-stimulating factor 1 receptor (CSF1R) inhibitors in cancer therapy. Cannarile MA et al. J Immunother Cancer. (2017)

Targeting tumor-associated macrophages with anti-CSF-1R antibody reveals a strategy for cancer therapy. Ries CH et al. Cancer Cell. (2014)

CSF-1/CSF-1R targeting agents in clinical development for cancer therapy. Ries CH et al. Curr Opin Pharmacol. (2015)

Search results

Items: 1 to 50 of 53

1.

Phase I Study of Emactuzumab Single Agent or in Combination with Paclitaxel in Patients with Advanced/Metastatic Solid Tumors Reveals Depletion of Immunosuppressive M2-like Macrophages.

Gomez-Roca CA, Italiano A, Le Tourneau C, Cassier PA, Toulmonde M, D'Angelo SP, Campone M, Weber KL, Loirat D, Cannarile MA, Jegg AM, Ries C, Christen R, Meneses-Lorente G, Jacob W, Klaman I, Ooi CH, Watson C, Wonde K, Reis B, Michielin F, Rüttinger D, Delord JP, Blay JY.

Ann Oncol. 2019 May 22. pii: mdz163. doi: 10.1093/annonc/mdz163. [Epub ahead of print]

PMID:
31114846
2.

Therapeutic targeting of macrophages enhances chemotherapy efficacy by unleashing type I interferon response.

Salvagno C, Ciampricotti M, Tuit S, Hau CS, van Weverwijk A, Coffelt SB, Kersten K, Vrijland K, Kos K, Ulas T, Song JY, Ooi CH, Rüttinger D, Cassier PA, Jonkers J, Schultze JL, Ries CH, de Visser KE.

Nat Cell Biol. 2019 Apr;21(4):511-521. doi: 10.1038/s41556-019-0298-1. Epub 2019 Mar 18.

PMID:
30886344
3.

Addressing current challenges and future directions in immuno-oncology: expert perspectives from the 2017 NIBIT Foundation Think Tank, Siena, Italy.

Maio M, Coukos G, Ferrone S, Fox BA, Fridman WH, Garcia PL, Lahn M, Provendier O, Russo V, Rüttinger D, Shalabi A, Trajanoski Z, Viallet J, Wolchok JD, Ibrahim R.

Cancer Immunol Immunother. 2019 Jan;68(1):1-9. doi: 10.1007/s00262-018-2285-y. Epub 2018 Dec 18.

PMID:
30564889
4.

Rapid activation of tumor-associated macrophages boosts preexisting tumor immunity.

Hoves S, Ooi CH, Wolter C, Sade H, Bissinger S, Schmittnaegel M, Ast O, Giusti AM, Wartha K, Runza V, Xu W, Kienast Y, Cannarile MA, Levitsky H, Romagnoli S, De Palma M, Rüttinger D, Ries CH.

J Exp Med. 2018 Mar 5;215(3):859-876. doi: 10.1084/jem.20171440. Epub 2018 Feb 7.

5.

Colony-stimulating factor 1 receptor (CSF1R) inhibitors in cancer therapy.

Cannarile MA, Weisser M, Jacob W, Jegg AM, Ries CH, Rüttinger D.

J Immunother Cancer. 2017 Jul 18;5(1):53. doi: 10.1186/s40425-017-0257-y. Review.

6.

[DGFIT: Immune and Targeted Therapy at ASCO 2016 - What will the Future Bring?]

Hegele A, Siebels M, Heinzer H, Rüttinger D.

Aktuelle Urol. 2016 Dec;47(6):e4-e8. doi: 10.1055/s-0042-112542. Epub 2016 Oct 27. German.

PMID:
27788527
7.

Macrophage Susceptibility to Emactuzumab (RG7155) Treatment.

Pradel LP, Ooi CH, Romagnoli S, Cannarile MA, Sade H, Rüttinger D, Ries CH.

Mol Cancer Ther. 2016 Dec;15(12):3077-3086. Epub 2016 Aug 31.

8.

First-in-human phase I clinical trial of RG7356, an anti-CD44 humanized antibody, in patients with advanced, CD44-expressing solid tumors.

Menke-van der Houven van Oordt CW, Gomez-Roca C, van Herpen C, Coveler AL, Mahalingam D, Verheul HM, van der Graaf WT, Christen R, Rüttinger D, Weigand S, Cannarile MA, Heil F, Brewster M, Walz AC, Nayak TK, Guarin E, Meresse V, Le Tourneau C.

Oncotarget. 2016 Nov 29;7(48):80046-80058. doi: 10.18632/oncotarget.11098.

9.

CSF1R inhibition with emactuzumab in locally advanced diffuse-type tenosynovial giant cell tumours of the soft tissue: a dose-escalation and dose-expansion phase 1 study.

Cassier PA, Italiano A, Gomez-Roca CA, Le Tourneau C, Toulmonde M, Cannarile MA, Ries C, Brillouet A, Müller C, Jegg AM, Bröske AM, Dembowski M, Bray-French K, Freilinger C, Meneses-Lorente G, Baehner M, Harding R, Ratnayake J, Abiraj K, Gass N, Noh K, Christen RD, Ukarma L, Bompas E, Delord JP, Blay JY, Rüttinger D.

Lancet Oncol. 2015 Aug;16(8):949-56. doi: 10.1016/S1470-2045(15)00132-1. Epub 2015 Jul 12.

PMID:
26179200
10.

CSF-1/CSF-1R targeting agents in clinical development for cancer therapy.

Ries CH, Hoves S, Cannarile MA, Rüttinger D.

Curr Opin Pharmacol. 2015 Aug;23:45-51. doi: 10.1016/j.coph.2015.05.008. Epub 2015 Jun 4. Review.

PMID:
26051995
11.

Targeting tumor-associated macrophages in cancer therapy and understanding their complexity.

Cannarile MA, Ries CH, Hoves S, Rüttinger D.

Oncoimmunology. 2014 Dec 13;3(9):e955356. eCollection 2014 Oct.

12.

Targeting tumor-associated macrophages with anti-CSF-1R antibody reveals a strategy for cancer therapy.

Ries CH, Cannarile MA, Hoves S, Benz J, Wartha K, Runza V, Rey-Giraud F, Pradel LP, Feuerhake F, Klaman I, Jones T, Jucknischke U, Scheiblich S, Kaluza K, Gorr IH, Walz A, Abiraj K, Cassier PA, Sica A, Gomez-Roca C, de Visser KE, Italiano A, Le Tourneau C, Delord JP, Levitsky H, Blay JY, Rüttinger D.

Cancer Cell. 2014 Jun 16;25(6):846-59. doi: 10.1016/j.ccr.2014.05.016. Epub 2014 Jun 2.

13.

Future of cancer vaccines.

Winter H, Fox BA, Rüttinger D.

Methods Mol Biol. 2014;1139:555-64. doi: 10.1007/978-1-4939-0345-0_40. Review.

PMID:
24619704
14.

Use of gastric residual volume to guide enteral nutrition in critically ill patients: a brief systematic review of clinical studies.

Kuppinger DD, Rittler P, Hartl WH, Rüttinger D.

Nutrition. 2013 Sep;29(9):1075-9. doi: 10.1016/j.nut.2013.01.025. Epub 2013 Jun 4. Review.

PMID:
23756283
15.

Prolonged overall survival after pulmonary metastasectomy in patients with breast cancer.

Meimarakis G, Rüttinger D, Stemmler J, Crispin A, Weidenhagen R, Angele M, Fertmann J, Hatz RA, Winter H.

Ann Thorac Surg. 2013 Apr;95(4):1170-80. doi: 10.1016/j.athoracsur.2012.11.043. Epub 2013 Feb 4.

PMID:
23391172
16.

[DGFIT: Immune and targeted therapy in urologic oncology – what can be expected?].

Hegele A, Heinzer H, Rüttinger D, Siebels M.

Aktuelle Urol. 2012 Jul;43(4):219-26. German.

PMID:
23035262
17.

Phase IB study of the EpCAM antibody adecatumumab combined with docetaxel in patients with EpCAM-positive relapsed or refractory advanced-stage breast cancer.

Schmidt M, Rüttinger D, Sebastian M, Hanusch CA, Marschner N, Baeuerle PA, Wolf A, Göppel G, Oruzio D, Schlimok G, Steger GG, Wolf C, Eiermann W, Lang A, Schuler M.

Ann Oncol. 2012 Sep;23(9):2306-13. doi: 10.1093/annonc/mdr625. Epub 2012 Feb 21.

PMID:
22357251
18.

Active-specific immunotherapy for non-small cell lung cancer.

Winter H, van den Engel NK, Rusan M, Schupp N, Poehlein CH, Hu HM, Hatz RA, Urba WJ, Jauch KW, Fox BA, Rüttinger D.

J Thorac Dis. 2011 Jun;3(2):105-14. doi: 10.3978/j.issn.2072-1439.2010.12.06.

19.

Acute prognosis of critically ill patients with secondary peritonitis: the impact of the number of surgical revisions, and of the duration of surgical therapy.

Rüttinger D, Kuppinger D, Hölzwimmer M, Zander S, Vilsmaier M, Küchenhoff H, Jauch KW, Hartl WH.

Am J Surg. 2012 Jul;204(1):28-36. doi: 10.1016/j.amjsurg.2011.07.019. Epub 2012 Jan 5.

PMID:
22226144
20.

Combination immunotherapy and active-specific tumor cell vaccination augments anti-cancer immunity in a mouse model of gastric cancer.

van den Engel NK, Rüttinger D, Rusan M, Kammerer R, Zimmermann W, Hatz RA, Winter H.

J Transl Med. 2011 Aug 22;9:140. doi: 10.1186/1479-5876-9-140.

21.

Evaluation of a new prognostic score (Munich score) to predict long-term survival after resection of pulmonary renal cell carcinoma metastases.

Meimarakis G, Angele M, Staehler M, Clevert DA, Crispin A, Rüttinger D, Löhe F, Preissler G, Hatz RA, Winter H.

Am J Surg. 2011 Aug;202(2):158-67. doi: 10.1016/j.amjsurg.2010.06.029.

PMID:
21810496
22.

Dendritic cell-based vaccination of patients with advanced pancreatic carcinoma: results of a pilot study.

Bauer C, Dauer M, Saraj S, Schnurr M, Bauernfeind F, Sterzik A, Junkmann J, Jakl V, Kiefl R, Oduncu F, Emmerich B, Mayr D, Mussack T, Bruns C, Rüttinger D, Conrad C, Jauch KW, Endres S, Eigler A.

Cancer Immunol Immunother. 2011 Aug;60(8):1097-107. doi: 10.1007/s00262-011-1023-5. Epub 2011 May 6.

PMID:
21547597
23.

Primary cervical carcinoma cell lines overexpress epithelial cell adhesion molecule (EpCAM) and are highly sensitive to immunotherapy with MT201, a fully human monoclonal anti-EpCAM antibody.

Richter CE, Cocco E, Bellone S, Bellone M, Casagrande F, Todeschini P, Rüttinger D, Silasi DA, Azodi M, Schwartz PE, Rutherford TJ, Pecorelli S, Santin AD.

Int J Gynecol Cancer. 2010 Dec;20(9):1440-7.

24.

Immunotherapy of peritoneal carcinomatosis with the antibody catumaxomab in colon, gastric, or pancreatic cancer: an open-label, multicenter, phase I/II trial.

Ströhlein MA, Lordick F, Rüttinger D, Grützner KU, Schemanski OC, Jäger M, Lindhofer H, Hennig M, Jauch KW, Peschel C, Heiss MM.

Onkologie. 2011;34(3):101-8. doi: 10.1159/000324667. Epub 2011 Feb 18.

PMID:
21358214
25.
26.

Side-by-side analysis of five clinically tested anti-EpCAM monoclonal antibodies.

Münz M, Murr A, Kvesic M, Rau D, Mangold S, Pflanz S, Lumsden J, Volkland J, Fagerberg J, Riethmüller G, Rüttinger D, Kufer P, Baeuerle PA, Raum T.

Cancer Cell Int. 2010 Nov 2;10:44. doi: 10.1186/1475-2867-10-44.

27.

Highly efficient elimination of colorectal tumor-initiating cells by an EpCAM/CD3-bispecific antibody engaging human T cells.

Herrmann I, Baeuerle PA, Friedrich M, Murr A, Filusch S, Rüttinger D, Majdoub MW, Sharma S, Kufer P, Raum T, Münz M.

PLoS One. 2010 Oct 18;5(10):e13474. doi: 10.1371/journal.pone.0013474.

28.

High-grade, chemotherapy-resistant ovarian carcinomas overexpress epithelial cell adhesion molecule (EpCAM) and are highly sensitive to immunotherapy with MT201, a fully human monoclonal anti-EpCAM antibody.

Richter CE, Cocco E, Bellone S, Silasi DA, Rüttinger D, Azodi M, Schwartz PE, Rutherford TJ, Pecorelli S, Santin AD.

Am J Obstet Gynecol. 2010 Dec;203(6):582.e1-7. doi: 10.1016/j.ajog.2010.07.041. Epub 2010 Sep 25.

29.

Phase II study of the human anti-epithelial cell adhesion molecule antibody adecatumumab in prostate cancer patients with increasing serum levels of prostate-specific antigen after radical prostatectomy.

Marschner N, Rüttinger D, Zugmaier G, Nemere G, Lehmann J, Obrist P, Baeuerle PA, Wolf A, Schmidt M, Abrahamsson PA, Reinhardt C, Heidenreich A.

Urol Int. 2010;85(4):386-95. doi: 10.1159/000318055. Epub 2010 Jul 2.

PMID:
20606402
30.

Immunotherapy of cancer: key findings and commentary on the third Tegernsee conference.

Rüttinger D, Winter H, van den Engel NK, Hatz R, Jauch KW, Fox BA, Weber JS.

Oncologist. 2010;15(1):112-8. doi: 10.1634/theoncologist.2009-0213. Epub 2010 Jan 8.

31.

Overexpression of EpCAM in uterine serous papillary carcinoma: implications for EpCAM-specific immunotherapy with human monoclonal antibody adecatumumab (MT201).

El-Sahwi K, Bellone S, Cocco E, Casagrande F, Bellone M, Abu-Khalaf M, Buza N, Tavassoli FA, Hui P, Rüttinger D, Silasi DA, Azodi M, Schwartz PE, Rutherford TJ, Pecorelli S, Santin AD.

Mol Cancer Ther. 2010 Jan;9(1):57-66. doi: 10.1158/1535-7163.MCT-09-0675. Epub 2010 Jan 6.

32.

An open-label, randomized phase II study of adecatumumab, a fully human anti-EpCAM antibody, as monotherapy in patients with metastatic breast cancer.

Schmidt M, Scheulen ME, Dittrich C, Obrist P, Marschner N, Dirix L, Schmidt M, Rüttinger D, Schuler M, Reinhardt C, Awada A.

Ann Oncol. 2010 Feb;21(2):275-82. doi: 10.1093/annonc/mdp314. Epub 2009 Jul 24.

PMID:
19633042
33.

Immunotherapy of lymphoma and leukemia with T-cell engaging BiTE antibody blinatumomab.

Nagorsen D, Bargou R, Ruttinger D, Kufer P, Baeuerle PA, Zugmaier G.

Leuk Lymphoma. 2009 Jun;50(6):886-91. doi: 10.1080/10428190902943077. Review.

PMID:
19455460
34.

Does surgical resection of pulmonary metastases of head and neck cancer improve survival?

Winter H, Meimarakis G, Hoffmann G, Hummel M, Rüttinger D, Zilbauer A, Stelter K, Spelsberg F, Jauch KW, Hatz R, Löhe F.

Ann Surg Oncol. 2008 Oct;15(10):2915-26. doi: 10.1245/s10434-008-0001-4. Epub 2008 Jul 22.

PMID:
18648883
35.

Increased susceptibility to immune destruction of B16BL6 tumor cells engineered to express a novel pro-Smac fusion protein.

Rüttinger D, Li R, Poehlein CH, Haley D, Walker EB, Hu HM, Fox BA.

J Immunother. 2008 Jan;31(1):43-51.

PMID:
18157011
36.

Current immunotherapeutic strategies in lung cancer.

Rüttinger D, Hatz RA, Jauch KW, Fox BA.

Surg Oncol Clin N Am. 2007 Oct;16(4):901-18, x. Review.

PMID:
18022551
37.

Therapeutic T cells induce tumor-directed chemotaxis of innate immune cells through tumor-specific secretion of chemokines and stimulation of B16BL6 melanoma to secrete chemokines.

Winter H, van den Engel NK, Rüttinger D, Schmidt J, Schiller M, Poehlein CH, Löhe F, Fox BA, Jauch KW, Hatz RA, Hu HM.

J Transl Med. 2007 Nov 14;5:56.

38.

Adjuvant therapeutic vaccination in patients with non-small cell lung cancer made lymphopenic and reconstituted with autologous PBMC: first clinical experience and evidence of an immune response.

Rüttinger D, van den Engel NK, Winter H, Schlemmer M, Pohla H, Grützner S, Wagner B, Schendel DJ, Fox BA, Jauch KW, Hatz RA.

J Transl Med. 2007 Sep 14;5:43.

39.

Predictors of general complications after video-assisted thoracoscopic surgical procedures.

Winter H, Meimarakis G, Pirker M, Spelsberg F, Kopp R, Rüttinger D, Loehe F, Jauch KW, Hatz R.

Surg Endosc. 2008 Mar;22(3):640-5.

PMID:
17623249
40.

Red cell transfusion: an essential factor for patient prognosis in surgical critical illness?

Rüttinger D, Wolf H, Küchenhoff H, Jauch KW, Hartl WH.

Shock. 2007 Aug;28(2):165-71.

PMID:
17529904
41.

Characterization of immune responses in gastric cancer patients: a possible impact of H. pylori to polarize a tumor-specific type 1 response?

van den Engel NK, Winter H, Rüttinger D, Shau I, Schiller M, Mayer B, Moudgil T, Meimarakis G, Stolte M, Jauch KW, Fox BA, Hatz RA.

Clin Immunol. 2006 Sep;120(3):285-96. Epub 2006 Jun 9.

PMID:
16765089
42.

Immunotherapy of lung cancer: an update.

Rüttinger D, Winter H, van den Engel NK, Hatz RA, Schlemmer M, Pohla H, Grützner S, Schendel DJ, Fox BA, Jauch KW.

Onkologie. 2006 Feb;29(1-2):33-8. Review.

PMID:
16514254
43.

Immunotherapy for melanoma: the good, the bad, and the future.

Poehlein CH, Rüttinger D, Ma J, Hu HM, Urba WJ, Fox BA.

Curr Oncol Rep. 2005 Sep;7(5):383-92. Review.

PMID:
16091201
44.

Manipulating the host response to autologous tumour vaccines.

Ma J, Poehlein CH, Jensen SM, LaCelle MG, Moudgil TM, Rüttinger D, Haley D, Goldstein MJ, Smith JW 3rd, Curti B, Ross H, Walker E, Hu HM, Urba WJ, Fox BA.

Dev Biol (Basel). 2004;116:93-107; discussion 133-43.

PMID:
15603186
45.
46.

Targeting and amplification of immune killing of tumor cells by pro-Smac.

Li R, Rüttinger D, Urba W, Fox BA, Hu HM.

Int J Cancer. 2004 Mar;109(1):85-94.

47.

Analysis of the immunological microenvironment at the tumor site in patients with non-small cell lung cancer.

Li R, Rüttinger D, Li R, Si LS, Wang YL.

Langenbecks Arch Surg. 2003 Dec;388(6):406-12. Epub 2003 Sep 19.

PMID:
14504933
48.

Evaluation of a preclinical model of bone metastasis for the study of adoptive immunotherapy.

Rüttinger D, Li R, Urba WJ, Fox BA, Hu HM.

Eur Surg Res. 2003 Jul-Aug;35(4):346-51.

PMID:
12802095
49.

Hypertonic saline dextran attenuates leukocyte accumulation in the liver after hemorrhagic shock and resuscitation.

Corso CO, Okamoto S, Rüttinger D, Messmer K.

J Trauma. 1999 Mar;46(3):417-23.

PMID:
10088843
50.

Failure of Kupffer cell blockade to prevent disseminated intravascular coagulation in endotoxemic rats despite improved survival.

Rüttinger D, Vollmar B, Kempter B, Messmer K.

Langenbecks Arch Surg. 1998 Mar;383(1):75-80.

PMID:
9627175

Supplemental Content

Loading ...
Support Center